Proteosomes, emulsomes, and cholera toxin B improve nasal Immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG

被引:61
作者
Lowell, GH
Kaminski, RW
VanCott, TC
Slike, B
Kersey, K
Zawoznik, E
LoomisPrice, L
Smith, G
Redfield, RR
Amselem, S
Birx, DL
机构
[1] WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV PATHOL,WASHINGTON,DC 20307
[2] WALTER REED ARMY INST RES,DEPT RETROVIRAL RES,ROCKVILLE,MD
[3] HENRY M JACKSON FDN,ROCKVILLE,MD
[4] PHARMOS CORP,ALACHUA,FL
[5] PHARMOS CORP,REHOVOT,ISRAEL
[6] MICROGENESYS INC,MERIDEN,CT
关键词
D O I
10.1093/infdis/175.2.292
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intranasal immunization of mice with human immunodeficiency virus (HIV) rgp160 complexed to proteosomes improved anti-gp160 serum IgA and IgG titers, increased the number of gp160 peptides recognized, and stimulated anti-gp160 intestinal IgA compared with immunization with uncomplexed rgp160 in saline, These enhanced responses were especially evident when either a bioadhesive nanoemulsion (emulsomes) or cholera toxin B subunit (CTB) was added to the proteosome-rgp160 vaccine, Furthermore, anti-gp160 Ige and IgA in vaginal secretions and fecal extracts were induced after intranasal immunization with proteosome-rgp160 delivered either in saline or with emulsomes, Formulation of uncomplexed rgp160 with emulsomes or CTB also enhanced serum and selected mucosal IgA responses, Induction of serum, vaginal, bronchial, intestinal, and fecal IgA and IgG by intranasal proteosome-rgp160 vaccines delivered in saline or with emulsomes or CTB is encouraging for mucosal vaccine development to help control the spread of HIV transmission and AIDS.
引用
收藏
页码:292 / 301
页数:10
相关论文
共 64 条
[41]  
LYCKE N, 1989, J IMMUNOL, V142, P3781
[42]   INTRANASAL OR INTRAGASTRIC IMMUNIZATION WITH PROTEOSOME-SHIGELLA LIPOPOLYSACCHARIDE VACCINES PROTECTS AGAINST LETHAL PNEUMONIA IN A MURINE MODEL OF SHIGELLA INFECTION [J].
MALLETT, CP ;
HALE, TL ;
KAMINSKI, RW ;
LARSEN, T ;
ORR, N ;
COHEN, D ;
LOWELL, GH .
INFECTION AND IMMUNITY, 1995, 63 (06) :2382-2386
[43]   PROTECTION AGAINST VAGINAL SIV TRANSMISSION WITH MICROENCAPSULATED VACCINE [J].
MARX, PA ;
COMPANS, RW ;
GETTIE, A ;
STAAS, JK ;
GILLEY, RM ;
MULLIGAN, MJ ;
YAMSHCHIKOV, GV ;
CHEN, DX ;
ELDRIDGE, JH .
SCIENCE, 1993, 260 (5112) :1323-1327
[44]   ASSOCIATION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-III ANTIBODIES WITH SEXUAL AND OTHER BEHAVIORS IN A COHORT OF HOMOSEXUAL MEN FROM BOSTON WITH AND WITHOUT GENERALIZED LYMPHADENOPATHY [J].
MAYER, KH ;
AYOTTE, D ;
GROOPMAN, JE ;
STODDARD, AM ;
SARNGADHARAN, M ;
GALLO, R .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (03) :357-363
[45]   A 3-TIERED VIEW OF THE ROLE OF IGA IN MUCOSAL DEFENSE [J].
MAZANEC, MB ;
NEDRUD, JG ;
KAETZEL, CS ;
LAMM, ME .
IMMUNOLOGY TODAY, 1993, 14 (09) :430-435
[46]   THE MUCOSAL IMMUNE-SYSTEM - FROM FUNDAMENTAL-CONCEPTS TO VACCINE DEVELOPMENT [J].
MCGHEE, JR ;
MESTECKY, J ;
DERTZBAUGH, MT ;
ELDRIDGE, JH ;
HIRASAWA, M ;
KIYONO, H .
VACCINE, 1992, 10 (02) :75-88
[47]   THE COMMON MUCOSAL IMMUNE-SYSTEM AND CURRENT STRATEGIES FOR INDUCTION OF IMMUNE-RESPONSES IN EXTERNAL SECRETIONS [J].
MESTECKY, J .
JOURNAL OF CLINICAL IMMUNOLOGY, 1987, 7 (04) :265-276
[48]   MUCOSAL MODEL OF IMMUNIZATION AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH A CHIMERIC INFLUENZA-VIRUS [J].
MUSTER, T ;
FERKO, B ;
KLIMA, A ;
PURTSCHER, M ;
TRKOLA, A ;
SCHULZ, P ;
GRASSAUER, A ;
ENGELHARDT, OG ;
GARCIASASTRE, A ;
PALESE, P ;
KATINGER, H .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6678-6686
[49]   IMMUNOGENICITY OF RECOMBINANT HUMAN ADENOVIRUS HUMAN-IMMUNODEFICIENCY-VIRUS VACCINES IN CHIMPANZEES [J].
NATUK, RJ ;
LUBECK, MD ;
CHANDA, PK ;
CHENGALVALA, M ;
WADE, MS ;
MURTHY, SCS ;
WILHELM, J ;
VERNON, SK ;
DHEER, SK ;
MIZUTANI, S ;
LEE, SG ;
MURTHY, KK ;
EICHBERG, JW ;
DAVIS, AR ;
HUNG, PP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (05) :395-404
[50]  
Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9